Overview
Northwest Healthcare Q2 2025 revenue falls 16.9% to C$99 million due to asset sales
Net income for Q2 2025 reaches C$32.6 mln, reversing prior year loss
Co suspends DRIP and appoints CEO Zachary Vaughan to Board
Outlook
Company manages rent deferral with Healthscope, expecting repayment by March 2026
Result Drivers
ASSET SALES - Revenue decreased 16.9% in Q2 2025 due to non-core asset sales, partially offset by same property revenue growth
SPNOI GROWTH - Same Property Net Operating Income increased by 2.8% driven by inflationary rent adjustments and improved recoveries
DEBT REDUCTION - Proceeds from asset sales used to repay debt, reducing leverage to 48.5% from 50.0% at year-end 2024
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income |
| C$32.62 mln |
|
Q2 FFO Per Share |
| C$0.11 |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the specialized reits peer group is "buy."
Wall Street's median 12-month price target for Northwest Healthcare Properties REIT is C$5.55, about 14.2% above its August 11 closing price of C$4.76
Press Release: ID:nNFC5HMZvh